UBS analyst Danielle Antalffy initiated coverage of RxSight (RXST) with a Buy rating and $52 price target The company’s Light Adjustable Lens competes in the $4B-plus U.S. cataract surgery market, and specifically within the $2B-$2.5B premium cash pay segment of the market, which is growing even faster, the analyst tells investors in a research note. The firm sees RxSight as well positioned to sustain its recent strong double digit growth rate, with its model projecting 20%-plus sales growth through 2028 and 18% in 2029.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight, Inc. Reports Strong Q3 Financial Results
- Closing Bell Movers: Toast gains 19% afterhours after earnings beat
- RxSight reports Q3 adjusted EPS 0c, consensus (25c)
- RxSight sees FY24 revenue $139M-$140M, consensus $139.64M
- Trade Desk downgraded, First Solar upgraded: Wall Street’s top analyst calls